Roche-backed Minoryx raises €21M to expand CNS R&D

Barcelona Spain
Barcelona, Spain, near to where Minoryx is based. (Pel_1971/iStock/Getty Images Plus/Getty Images)

Minoryx has raised €21.3 million in series B funding. The round sets Minoryx up to expand clinical development of a neurodegenerative disease drug that has attracted the interest of organizations including Roche Venture Fund.

Spain’s Minoryx established itself as an emerging player in neurodegeneration R&D in 2015 when it raised a €19.4 million series A round to take PPAR-gamma agonist MIN-102 into clinical trials. Three years later, Minoryx has advanced MIN-102 into a phase 2/3 trial in patients with the inherited spinal cord condition adrenomyeloneuropathy.

With the phase 2/3 trial heading toward a 2020 readout, Minoryx wants to assess the potential of MIN-102 in more indications.

Survey

Industry Insight Survey: Direct-to-Patient Distribution of Clinical Supplies

This industry survey seeks to gain insight on trial sponsors' perspective on offering a DTP option and their current level of awareness and understanding of any factors that may influence their ability to do so. The first 50 qualified respondents will receive a $5 Amazon gift card.

“The proceeds of the round will allow the company to demonstrate the potential of MIN-102 in new indications,” Minoryx CEO Marc Martinell said in a statement. “These indications for MIN-102 include neuroinflammatory conditions such as cerebral ALD as well as multiple neurodegenerative diseases.”

Belgian VC shop Fund+ has facilitated Minoryx’s plan by leading a series B round that attracted the support of existing backers including Ysios Capital and Roche Venture Fund. The syndicate’s willingness to bankroll Minoryx’s expansion plans reflects the early promise shown by MIN-102 and the evidence suggesting PPAR agonists have neuroprotective effects.

Researchers have been studying the neuroprotective potential of PPAR agonists since the early 2000s and drugs from Eli Lilly, GlaxoSmithKline and others have been through early-stage assessments in this context.

However, while PPAR-gamma agonists including GlaxoSmithKline’s Avandia have come to market in diabetes—and promptly run into trouble—the CNS potential of the class remains unrealized. Minoryx thinks MIN-102 has the attributes to unlock this potential. Crucially, results from a phase 1 trial and other studies suggest MIN-102 crosses the blood-brain barrier and interacts with its target.

Suggested Articles

Support for specialty therapies with a tech-based platform that challenges the old hub model and improves the patient journey.

Abbott teamed up with Omada Health to offer its FreeStyle Libre CGM system through the latter’s digital care program for type 2 diabetes.

Eli Lilly is closing down its U.K.-based Erl Wood neuroscience in Surrey, leading to cuts and relocations.